Saverymuttu S H, Peters A M, Lavender J P, Hodgson H J, Chadwick V S
Gut. 1983 Apr;24(4):293-9. doi: 10.1136/gut.24.4.293.
A non-invasive method of imaging and assessing inflammatory bowel disease is described. 111Indium labelled leucocyte scans were performed on 33 patients with a wide variety of inflammatory bowel diseases and 25 control patients. All patients with moderate or severe inflammatory bowel disease had positive scans with localisation of abnormal activity corresponding to the sites assessed to be diseased by radiology in either small or large bowel. No false positives were recorded in the control patients. Faecal excretion of 111In labelled leucocytes was increased in patients with inflammatory bowel disease according to disease severity and correlated with disease activity assessed by serum C-reactive protein levels (r = 0.74, p less than 0.001) or in those patients with Crohn's disease by Crohn's Disease Activity Index (r = 0.78, p less than 0.001). These data suggest that 111In labelled leucocytes may be used to provide a safe, non-invasive method of imaging diseased bowel and objectively assessing disease activity.
描述了一种用于成像和评估炎症性肠病的非侵入性方法。对33例患有各种炎症性肠病的患者和25例对照患者进行了铟-111标记白细胞扫描。所有中度或重度炎症性肠病患者的扫描结果均为阳性,异常活性的定位与经放射学评估为病变的小肠或大肠部位相对应。对照患者中未记录到假阳性。炎症性肠病患者中,铟-111标记白细胞的粪便排泄量根据疾病严重程度而增加,并且与通过血清C反应蛋白水平评估的疾病活动相关(r = 0.74,p < 0.001),或在克罗恩病患者中与克罗恩病活动指数相关(r = 0.78,p < 0.001)。这些数据表明,铟-111标记白细胞可用于提供一种安全、非侵入性的成像病变肠段并客观评估疾病活动的方法。